Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ALLK - Allakos Inc.
Market Cap 475.22M P/E - EPS this Y 28.00% Ern Qtrly Grth -
Income -206M Forward P/E -2.92 EPS next Y 57.10% 50D Avg Chg 15.00%
Sales - PEG -0.02 EPS past 5Y - 200D Avg Chg -5.00%
Dividend N/A Price/Book 1.69 EPS next 5Y 26.70% 52W High Chg -37.00%
Recommedations 2.90 Quick Ratio 3.43 Shares Outstanding 88.85M 52W Low Chg 66.00%
Insider Own 2.33% ROA -49.29% Shares Float 59.22M Beta 1.15
Inst Own 88.10% ROE -121.54% Shares Shorted/Prior 1.96M/2.31M Price 5.49
Gross Margin - Profit Margin - Avg. Volume 1,022,683 Target Price 2.77
Oper. Margin - Earnings Date Nov 11 Volume 705,580 Change -1.08%
Healthcare | Biotechnology | United States
About Allakos Inc.

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Inc. News
11/29/24 3 US Penny Stocks Under $200M Market Cap To Watch
11/11/24 All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
11/06/24 Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
10/22/24 3 US Penny Stocks With Market Caps Larger Than $50M
10/10/24 Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
08/07/24 Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
07:33 AM Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
06/25/24 Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
05/28/24 Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
05/10/24 Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
05/09/24 Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
05/03/24 With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners
04/04/24 Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
03/16/24 Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
03/14/24 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
02/26/24 Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
02/12/24 Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
01/18/24 Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
01/18/24 Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
01/17/24 Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Tomasi Adam President and COO President and COO Jun 07 Sell 91.15 3,129 285,208 150,707 06/07/21
RASMUSSEN HENRIK S MD Chief Medical Office.. Chief Medical Officer Jun 04 Sell 89.6 2,435 218,176 98,550 06/04/21
Alexander Robert Chief Executive Offi.. Chief Executive Officer May 19 Option 0.69 43,550 30,049 259,912 05/19/21
Alexander Robert Chief Executive Offi.. Chief Executive Officer May 19 Sell 100.31 43,550 4,368,500 245,395 05/19/21
Tomasi Adam President and COO President and COO May 13 Option 0.69 60,000 41,400 173,126 05/13/21
Tomasi Adam President and COO President and COO May 13 Sell 97.68 60,000 5,860,800 153,126 05/13/21
Tomasi Adam President, COO and C.. President, COO and CFO Apr 14 Option 0.69 60,000 41,400 173,126 04/14/21
Tomasi Adam President, COO and C.. President, COO and CFO Apr 14 Sell 105.08 60,000 6,304,800 153,126 04/14/21
RASMUSSEN HENRIK S MD Chief Medical Office.. Chief Medical Officer Apr 06 Sell 113.05 50,000 5,652,500 101,819 04/06/21
RASMUSSEN HENRIK S MD Chief Medical Office.. Chief Medical Officer Apr 06 Option 1.16 50,000 58,000 121,819 04/06/21
MCKEARN JOHN P Director Director Mar 30 Sell 115 7,439 855,485 1,200 03/30/21
JANNEY DANIEL Director Director Mar 30 Sell 115.55 17,308 1,999,939 56,293 03/30/21
JANNEY DANIEL Director Director Mar 24 Sell 119.84 13,148 1,575,656 73,601 03/24/21
NOHRA GUY P 10% Owner 10% Owner Mar 08 Sell 111.33 25,768 2,868,751 03/08/21
MORE ROBERT J Other Other Mar 05 Sell 114.61 32,554 3,731,014 03/05/21
Tomasi Adam President, COO and C.. President, COO and CFO Mar 03 Sell 113.56 3,189 362,143 153,126 03/03/21
RASMUSSEN HENRIK S MD Chief Medical Office.. Chief Medical Officer Mar 03 Option 1.16 60,000 69,600 125,087 03/03/21
RASMUSSEN HENRIK S MD Chief Medical Office.. Chief Medical Officer Mar 03 Sell 115.95 61,952 7,183,334 105,087 03/03/21
Walker Paul Edward Director Director Jan 04 Sell 141.66 103,415 14,649,769 2,163,260 01/04/21